CLG-AVR1.03		Page 1 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

Contents

A.	INTRODUCTION2
B.	EQUIPMENT2
C.	REAGENTS AND SOLUTIONS
D.	STANDARDS4
E.	SAMPLE PREPARATION5
F.	ANALYTICAL PROCEDURE5
G.	CALCULATIONS
H.	SAFETY INFORMATION AND PRECAUTIONS
l.	QUALITY ASSURANCE PLAN
J.	WORKSHEET14
K.	APPENDIX15
L.	APPROVALS AND AUTHORITIES18

CLG-AVR1.03		Page 2 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

A. INTRODUCTION

1. Theory

The acetonitrile extract obtained from the determinative method (CLG-AVR) prior to derivatization for LC analysis is further purified by using a C8 solid phase extraction (SPE) cartridge and an alumina-B SPE cartridge. The purified extract is analyzed by injecting into an LC/APCI mass spectrometer. The identity of the compound is confirmed by comparison of its retention time and relative intensity with those of a standard or a positive control.

2. Applicability

This method is applicable for confirmation of Ivermectin, Doramectin and Moxidectin in liver and muscle of bovine, ovine, porcine, caprine and equine species as well as their processed products at \geq 25 ppb.

Note: Occasionally, some additives may interfere with confirmation of low level findings.

B. EQUIPMENT

Note: Equivalent apparatus or instrumentation may be substituted for any of the following.

1. Apparatus

- a. Amber ABC screw-top vials 2 mL Cat. No. 27331, Supelco.
- b. EDP Plus Micropipettes 250 μL capacity, Rainin Instrument Inc.
- Mechanical shaker Eberbach model 610 equipped with shaker box model 6040, Thomas Scientific.
- d. Vortex mixer Fisher Scientific, Fisher Scientific.
- e. 50-mL polypropylene centrifuge tubes Cat. No. 2098, Becton Dickerson Labware.
- f. 16-port Vacuum manifold Altech Associates, Inc.
- g. 15 mL disposable glass conical centrifuge tubes with snap caps, Cat No. 21020, VWR.
- h. N-Evap Model 112, Organomation Assoc. Inc.

CLG-AVR1.03		Page 3 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

- i. C8 Bond Elut cartridge Part No. 1210-2002, Varian.
- j. Sep-Pak Plus Alumina B Cartridge Part No. WAT 020505, Waters Corporation.

2. Instrumentation

a. LC/APCI MS - Waters 2690 LC with Waters/Micromass QA MS

LC column - Waters Nova-Pak 15 cm x 2 mm id. C-18, 4 μ m particles with an Optigard 1mm. C-18 guard column. LC column temperature at approximately 23 $^{\circ}$ C.

C. REAGENTS AND SOLUTIONS

Note: Equivalent reagents and solutions may be substituted for any of the following.

1. Reagents

- a. Acetonitrile (ACN) HPLC grade.
- b. Methanol HPLC grade.
- c. Water HPLC grade.
- d. Hexane HPLC grade.
- e. Triethylamine HPLC grade.
- f. Methylene chloride HPLC grade.
- g. Ethyl acetate HPLC Grade.

2. Solutions

- a. SPE wash solution ACN + water + triethylamine (30 mL + 70 mL + 0.1 mL).
 Make fresh immediately prior to use.
- b. 50 mM Ammonium Acetate Buffer Use the following formula to calculate the amount of ammonium acetate needed.
 - mg of ammonium acetate = $50 \times \text{Liter}$ of buffer needed x 77.08.
 - The ammonium acetate is dissolved in deionized water and adjusted with acetic acid to pH 4.
- c. LC Mobile Phase 70% ACN + 25% water + 5% Buffer (v/v).

Note: It is possible to shorten the retention times of the compound of interest for cleaner samples by increasing the flow rate or decreasing the % water in the mobile phase. With dirtier sample extracts, it may be necessary to change the

CLG-AVR1.03		Page 4 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

retention time by replacing some of the water with methanol, reducing the acetonitrile level or increasing the % of water.

d. Methylene Chloride/Ethyl Acetate (3:1):

Mix one volume of ethyl acetate to three volumes of methylene chloride.

D. STANDARDS

1. Source

a. Ivermectin standard catalog no. L-640,471-076P004

Merck, Sharpe and Dhome

Rahway, NJ 07065

b. Abamectin standard catalog no. L-676-863-038A003

Merck Sharpe and Dhome

Rahway, NJ 07065

c. Doramectin standard

Pfizer

Lee-Summit, MO 64081-2998

d. Moxidectin standard-catalog no. 301423

Fort Dodge Animal Health

Division of Wyeth

P.O. Box 5366

Princeton, NJ 08543-5366

2. Preparation of Standard Solutions

a. Stock standard solution (125 μg/mL):

Dissolve an appropriate amount of moxidectin, doramectin, and ivermectin separately in acetonitrile to make a concentration of 125 μ g/mL.

b. Working standard solution (0.5 μ g/mL):

Dilute 1 mL of each stock solution (a) to 250 mL with acetonitrile in a 250 mL volumetric flask. Use this working solution as the fortification solution for positive control and standard.

CLG-AVR1.03		Page 5 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

3. Storage conditions:

- Store stock solution in freezer.
- b. Working standard solutions may be stored at room temperature.

4. Shelf Life Stability

a. Stock: 1 year.

b. Working solution: 90 days.

E. SAMPLE PREPARATION

Weigh, extract, and clean up the sample as described in Determinative Method (CLG-AVR), section F.1.a. through F.1.f.

Note: Fortify the positive control with the Avermectin(s) of interest or the multiavermectin working standard at a concentration equivalent to that of the compound of interest.

F. ANALYTICAL PROCEDURE

1. Extraction Procedure

- a. Immediately following step F.1.f. of the Determinative Method (CLG-AVR) add 5 mL of hexane and vortex for 30 sec.
- b. Centrifuge for 3 min. at 2500 rpm or allow to stand until layers separate (approximately 5 min.). Remove and discard hexane top layer.
- c. Evaporate acetonitrile under a gentle stream of dry nitrogen or dry air at approximately 65 ± 5 °C.
- d. Reconstitute the dried sample using 5.0 mL \pm 50 μ L acetonitrile. Vortex to mix.
- e. Add 10 mL HPLC grade water and 50 μ L triethylamine. Vortex for 1 min. or shake vigorously for 5 min.
- f. Precondition a C8 Bond-Elut SPE cartridge by passing 4 mL ACN followed by 3 mL SPE wash solution.
- g. Pass extract in aliquots through the preconditioned C8 Bond Elut SPE cartridge with 10 mL reservoir until all extracts have been added at a flow rate of one drop per sec. Use a vacuum manifold to control the flow rate.
- h. Rinse empty sample tube with 3 mL SPE wash and add onto the SPE cartridge; discard eluates.

CLG-AVR1.03		Page 6 of 18	
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.			
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011	

- i. Dry SPE cartridge using a vacuum manifold for 5 minutes under vacuum (< 5 in. Hg).
- j. Elute Avermectin residues with 6 mL of acetonitrile into a clean centrifuge tube.
- k. Discard the C8 cartridges.

Note: Irreversible adsorption of the analytes to the C8 cartridge may occur and may result in decreased recovery of the analyte. The use of a different solvent to elute the Avermectin residues off the column may be necessary. For example: 3:1 methylene chloride/ethyl acetate or another solvent may be substituted for the acetonitrile as needed.

- I. Evaporate the eluate to dryness on a nitrogen evaporator at 60 ± 5 °C and reconstitute with 6 mL of 3:1 methylene chloride/ethyl acetate solution. Add onto a pre-washed Alumina-B cartridge [Pre-washed with 4 mL methylene chloride and dried for 1 min. under vacuum (< 5 in. Hg)]. Discard eluates.
- m. Draw air through Alumina-B cartridge for 30 sec.
- n. Use a clean 15 mL centrifuge tube to collect eluates.
- o. Attach a 10 mL Luer tip syringe to the cartridge. Pass 1.0 mL acetone through the Alumina B cartridge using gravity flow while collecting the eluate.
- p. Allow cartridge to drain and continue elution with 4 mL of methanol using gravity flow.
- q. Evaporate the eluate to dryness on a nitrogen evaporator at 60 ± 5 °C and reconstitute with 200 μ L of Mobile phase (C.2.c).
- r. Confirm residues by injecting into a LC/APCI mass spectrometer.
- 2. LC/APCI Mass Spectrometer operating conditions:

Note: It may be necessary to optimize the parameters when different mass spectrometers are used. The key parameters include the vaporizer and capillary temperature, the voltage of the capillary and the tube lens, the resolution of the mass spectrometer, the way of tuning, and the flow rate and composition of the LC mobile phase.

- a. Flow rate 0.5 mL/min.
- b. APCI probe temperature 500 °C
- c. Source temperature 140 °C
- d. Ionization mode Positive ion APCI
- e. Corona discharge current 5 μA

CLG-AVR1.03		Page 7 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

- f. Desolvation gas flow rate 450 L/hr.
- g. Cone gas flow rate 50 L/hr.
- h. Tune and calibration compounds Avermectin of interest or compounds with known spectra to cover the mass range of the ions monitored.
- i. Electron multiplier voltage 800 volts
- j. Peak width at 50% peak height 0.5 μm or larger.
- k. Window width of each ion 0.3 to 0.6 amu.
- I. Dwell time of each ion 250 ms.
- m. Scanning mode Selected ion monitoring.

3. LC/MS confirmation criteria:

- a. At least three characteristic ions, including the molecular weight ion, should be present.
- b. Two or more relative abundances are \pm 20% of the fortified sample (or the standard) run on the same day under the same conditions.
- c. The retention time is \pm 5% of the average of the standard or fortified sample.
- d. The tissue blank has no confirmable target compound.
- e. The signal to noise (S/N) ratio for the ions ratioed is > 3.

CLG-AVR1.03		Page 8 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

Table 1 shows the summary of fragment ions useful for confirmation of ivermectin, doramectin, and moxidectin.

Compound	Mode	Ion 1	lon 2	lon 3	lon 4	lon 5
		m/z	m/z	m/z	m/z	m/z
Ivermectin	+ APCI	892.5	567.3	551.3	307.2	569.3
	- APCI	873.5	855.5	567.3	837.5	
Doramectin	+ APCI	916.5	899.5	593.3	575.3	331.2
Moxidectin	+ APCI	640.4	622.4	498.3	496.3	528.3
Other ions may include	+ APCI	510.3	604.4	590.4		

CLG-AVR1.03		Page 9 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

- Sample Chromatograms
 See APPENDIX K.1 (a-c) for chromatograms.
- 5. Tentative fragmentation patterns:
 - a. Ivermectin.


OCH₃
HO

$$+2$$
 $+(731.4)$
 $-H_2O$
 $+H_2O$
 $+$

Figure 4. Tentative fragmentation pattern of ivermectin

CLG-AVR1.03		Page 10 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011


b. Doramectin



m/z	
916	$[M + NH_4]^+$
899	[M + H] ⁺
593	$[A]^{^{+}}$
575	$[A - H_2O]^+$
331	[B] ⁺

CLG-AVR1.03		Page 11 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

c. Moxidectin



m/z	
640	$[M + H]^{+}$
622	$[M + H - H_2O]^+$
498	[M – B – (CH ₃ CH ₂ CH ₂) ⁺ + H] ⁺
496	[M − A − CH ₃ OH + H] ⁺
528	[M – A + H] ⁺

G. CALCULATIONS

[Reserved]

H. SAFETY INFORMATION AND PRECAUTIONS

1. Required Protective Equipment - Safety glasses, appropriate gloves, lab coat.

CLG-AVR1.03		Page 12 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

2. Hazards

Reagents	Hazard	Recommended Safe Procedures
Acetonitrile, Methanol, Acetone, Ethyl acetate, Triethylamine, Hexane, Methylene Chloride	Flammable and corrosive, may cause skin or respiratory irritation.	Avoid contact or prolonged exposure to vapors. Work in a fume hood. Keep away from flame or heat.
Ivermectin Abamectin	Weak teratogen and possible mutagen.	Handle with extreme caution.
Doramectin	Severe explosion hazard.	Handle with extreme caution.
Moxidectin	May cause skin or respiratory irritation. The toxic effects of this material have not been fully evaluated.	Work in a well-ventilated area. Store material in a secure, dry, cool well ventilated room.

3. Disposal Procedures

Reagents

3.0		
Organic solvents	See above	Collect waste in tightly sealed container and store away from non-compatibles in a cool, well ventilated, flammable liquid storage area/cabinet for disposal in accordance with local, state, and Federal regulations.

Recommended Safe Procedures

Hazard

I. QUALITY ASSURANCE PLAN

1. Performance Standard

CLG-AVR1.03		Page 13 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

- a. No false positive in tissue blank for all compounds.
- b. No false negatives in the positive control at 25 ppb for all compounds.
- 2. Critical Control Points and Specifications

Record Acceptable Control

a. Sample weight

 $2.5~g.\pm0.2~g$

b. Final dilution volume

200 μL

3. Readiness To Perform

- Familiarization
 - Phase I: Standards Inject standards at the limit of confirmation and determine the ratios of the ions of interest for each component peak of compounds to be studied. Determine instrument sensitivity for each compound of interest.
 - ii. Phase II: Fortified samples For each species and tissue to be monitored, clean up and inject:
 - (a) A blank tissue extract
 - (b) A positive control for all compounds of interest at the tolerance level or at the lowest confirmable level.

Note: Phase I and Phase II may be performed concurrently.

- iii. Phase III: Check samples for analyst accreditation.
 - (a) Analyze a total of 8 samples in the tissues and species to be monitored. Samples should include liver, muscle, and processed products fortified at 25 ppb. At least one but no more than two should be blank. The fortification levels of the samples should be unknown to the analyst.
 - (b) Authorization from the QAM and Supervisor is required to commence official sample analysis
- b. Acceptability criteria.

Must meet confirmation criteria in section F.3 and I.1.

CLG-AVR1.03		Page 14 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

- 4. Intralaboratory Check Samples
 - a. Frequency: Once per week per analyst when samples are analyzed.
 - b. Records are to be maintained
 - c. Acceptability criteria.

If unacceptable values are obtained, then:

- i. Stop all official analyses by that analyst for this method.
- ii. Take corrective action.
- 5. Sample Acceptability and Stability
 - a. Matrix: Liver, muscle, and processed product.
 - b. Sample size: 1 lb. Minimum.
- 6. Sample storage:
 - a. Time: 6 months.
 - b. Condition: Frozen
- 7. Sample Set
 - a. Each set should include:
 - i. Tissue blank
 - ii. Positive control fortified at level comparable with the amount found using the determinative method
 - iii. Samples
 - iv. Standard
- 8. Sensitivity

Minimum Level of Applicability (MLA): 25 ppb

J. WORKSHEET


[Reserved]

CLG-AVR1.03		Page 15 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

K. APPENDIX


1. Chromatograms

a. Chromatograms of standards




CLG-AVR1.03		Page 16 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

b. Chromatograms of Beef Muscle Positive Control



CLG-AVR1.03		Page 17 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

c. Chromatograms of Beef Liver Positive Control



CLG-AVR1.03		Page 18 of 18
Title: Liquid Chromatography/Atmospheric Pressure Chemical Ionization Mass Spectrometric (LC/APCI/MS) Confirmation of Ivermectin, Doramectin and Moxidectin.		
Revision: 03	Replaces: CLG-AVR1.02	Effective: 03/31/2011

2. Reference

Journal of AOAC International Vol. 83, 39-52, 2000.

L. APPROVALS AND AUTHORITIES

Approvals on file.

Issuing Authority: Director, Laboratory Quality Assurance Division (LQAD).